康希诺生物(06185.HK):Ad5-nCoV与阿斯利康及强生病毒载体不同 百万人接种未有血栓相关严重不良报告
康希诺生物(06185.HK)指,注意到部分媒体有关接种阿斯利康新冠疫苗和强生新冠疫苗後个人出现罕见和严重血栓病例有关的报道。
公司指出,重组新型冠状病毒疫苗(5型腺病毒载体)「Ad5-nCoV」的载体为5型腺病毒,一种常见的感染人的腺病毒,与阿斯利康新冠疫苗所使用的黑猩猩腺病毒载体和强生新冠疫苗所使用的26型腺病毒载体不同。
截至公告日,接种Ad5-nCoV的约百万人中未收到与血栓相关的严重不良事件的报告。(el/a) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.